Sugi Predict

Sugi Predict / Compounds / SCHEMBL20116622

SCHEMBL20116622

SCHEMBL20116622

Cc1nn(C)c2ccc(/C(N)=N/O)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 2/20 0.47
▸ ADORA2B P29275 2/20 0.47
▸ CHRM4 P08173 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ KDM4E B2RXH2 4/20 0.38
▸ HPGD P15428 2/20 0.38
▸ HTT P42858 2/20 0.38
▸ LMNA P02545 4/20 0.37
▸ GFER P55789 2/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ BRAF P15056 1/20 0.36
▸ MAPK3 P27361 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ MAPT P10636 2/20 0.36
▸ PIM3 Q86V86 1/20 0.36
▸ PIM2 Q9P1W9 1/20 0.36
▸ GRM4 Q14833 1/20 0.34
▸ LSS P48449 1/20 0.34
▸ QPCT Q16769 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20660789 1.00 ADORA2A (0.47) ADORA2AADORA2BCHRM4RECQLKDM4E
SCHEMBL30506277 1.00 ADORA2A (0.47) ADORA2AADORA2BCHRM4RECQLKDM4E
SCHEMBL20116298 0.88 ADORA2A (0.47) ADORA2AADORA2BRECQLKDM4EHPGD
SCHEMBL20660978 0.88 ADORA2A (0.47) ADORA2AADORA2BRECQLKDM4EHPGD
SCHEMBL29520762 0.81 ADORA2A (0.50) ADORA2AADORA2BCHRM4KDM4EKMT2A
SCHEMBL21611310 0.79 ADORA2A (0.45) ADORA2AADORA2BCHRM4KDM4EHPGD
SCHEMBL20117026 0.79 ADORA2A (0.45) ADORA2AADORA2BCHRM4KDM4EHPGD
SCHEMBL23535727 0.76 HCAR3 (0.55) ADORA2AADORA2BCHRM4KDM4EHPGD
SCHEMBL14595343 0.76 ADORA2A (0.52) ADORA2AADORA2BCHRM4KDM4EHPGD
SCHEMBL30040739 0.76 HCAR3 (0.55) ADORA2AADORA2BCHRM4KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12275723-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2025-04-15 — — US disclosed
US-20240400546-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-12-05 — — US disclosed
US-20240300938-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-09-12 — — US disclosed
US-11970486-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-04-30 — — US disclosed
US-20240124435-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-04-18 — — US disclosed
CN-117777121-A Compounds and uses thereof 詹森药业有限公司 2024-03-29 — — CN disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
CN-110099898-B Compounds and uses thereof 优曼尼蒂治疗公司 2023-07-25 — — CN disclosed
EP-3700934-A1 COMPOUNDS AND USES THEREOF Yumanity Therapeutics, Inc. (US) 2020-09-02 — — EP disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 — — US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 — — US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 — — WO disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 — — WO disclosed
EP-3529245-A1 COMPOUNDS AND USES THEREOF Yumanity Therapeutics, Inc. (US) 2019-08-28 — — EP disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 — — WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 — — WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 — — WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124435-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 ADORA2A 687/4885ADORA2B 391/4885CHRM4 827/4885
US-20240300938-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 ADORA2A 687/4885ADORA2B 391/4885CHRM4 827/4885
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 ADORA2A 687/4885ADORA2B 391/4885CHRM4 827/4885
US-20240400546-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 ADORA2A 687/4885ADORA2B 391/4885CHRM4 827/4885
US-12275723-B2 Compounds and uses thereof NLN, ACHE, CLN6 ADORA2A 687/4885ADORA2B 391/4885CHRM4 827/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 ADORA2A 687/4885ADORA2B 391/4885CHRM4 827/4885
US-11970486-B2 Compounds and uses thereof NLN, ACHE, CLN6 ADORA2A 687/4885ADORA2B 391/4885CHRM4 827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.